CN Patent

CN113573705A — 鼻内利多卡因的治疗组合物

Assigned to Arcati Pharmaceuticals Usa · Expires 2021-10-29 · 5y expired

What this patent protects

公开了一种鼻用喷雾制剂和使用局部作用的钠通道阻滞剂治疗疼痛的方法,其中,鼻用喷雾制剂包含:约5%至约30%w/v的局部活性钠通道阻滞剂、约0.25%至约5%w/v的缓冲剂,以及约5%至约99%w/v的用于鼻腔施用的药学上可接受的载体。鼻用喷雾制剂优选包含在多剂量机械泵中,该多剂量机械泵以宽羽流和小液滴尺寸喷射单位剂量的鼻用喷雾制剂,使得通过启动多剂量机械喷雾泵装置并将一定体积的鼻用喷雾制剂喷入人类受试者的每个鼻孔中来施用单位剂量。优选地,鼻用喷雾制剂不包含防腐剂。

USPTO Abstract

公开了一种鼻用喷雾制剂和使用局部作用的钠通道阻滞剂治疗疼痛的方法,其中,鼻用喷雾制剂包含:约5%至约30%w/v的局部活性钠通道阻滞剂、约0.25%至约5%w/v的缓冲剂,以及约5%至约99%w/v的用于鼻腔施用的药学上可接受的载体。鼻用喷雾制剂优选包含在多剂量机械泵中,该多剂量机械泵以宽羽流和小液滴尺寸喷射单位剂量的鼻用喷雾制剂,使得通过启动多剂量机械喷雾泵装置并将一定体积的鼻用喷雾制剂喷入人类受试者的每个鼻孔中来施用单位剂量。优选地,鼻用喷雾制剂不包含防腐剂。

Drugs covered by this patent

Patent Metadata

Patent number
CN113573705A
Jurisdiction
CN
Classification
Expires
2021-10-29
Drug substance claim
No
Drug product claim
No
Assignee
Arcati Pharmaceuticals Usa
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.